Cardiol Therapeutics Company Leadership
| CRDL Stock | USD 1.33 0.03 2.21% |
Cardiol Therapeutics employs about 7 people. The company is managed by 7 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive. Inspection of Cardiol Therapeutics' management performance can provide insight into the company performance.
Cardiol |
Cardiol Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.5415) % which means that it has lost $0.5415 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0844) %, meaning that it created substantial loss on money invested by shareholders. Cardiol Therapeutics' management efficiency ratios could be used to measure how well Cardiol Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.81. The value of Return On Capital Employed is expected to slide to -1.1. At this time, Cardiol Therapeutics' Total Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 610.6 K this year, although the value of Non Currrent Assets Other are projected to rise to (0.95).The value of Common Stock Shares Outstanding is expected to slide to about 41.5 M. The value of Net Loss is expected to slide to about (29.2 M)
Cardiol Therapeutics Workforce Comparison
Cardiol Therapeutics Class is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 172. Cardiol Therapeutics adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Cardiol Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Cardiol Therapeutics Price Series Summation is a cross summation of Cardiol Therapeutics price series and its benchmark/peer.
Cardiol Therapeutics Notable Stakeholders
A Cardiol Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cardiol Therapeutics often face trade-offs trying to please all of them. Cardiol Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cardiol Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| David MBA | CEO President | Profile | |
| Andrew MD | Chief Development | Profile | |
| Trevor Burns | Investor Relations | Profile | |
| Bernard BSc | Chief Officer | Profile | |
| MBA BSCPT | Vice Development | Profile | |
| MBA MBA | CEO Pres | Profile | |
| CA CMA | Corp CFO | Profile |
About Cardiol Therapeutics Management Performance
The success or failure of an entity such as Cardiol Therapeutics often depends on how effective the management is. Cardiol Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cardiol management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cardiol management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.77) | (0.81) | |
| Return On Capital Employed | (1.05) | (1.10) | |
| Return On Assets | (0.77) | (0.80) | |
| Return On Equity | (1.00) | (1.05) |
Cardiol Therapeutics Workforce Analysis
Traditionally, organizations such as Cardiol Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cardiol Therapeutics within its industry.Cardiol Therapeutics Manpower Efficiency
Return on Cardiol Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 4K | |
| Net Loss Per Executive | 4K | |
| Working Capital Per Employee | 7.4M | |
| Working Capital Per Executive | 7.4M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.38) | Return On Assets (0.54) | Return On Equity (1.08) |
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.